Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Active not recruiting 2Recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 54Thoracic 8Gynecologic 7Head & Neck 6Genitourinary 6Dermatologic 4Breast 4Other solid neoplasm 1

Conditions

Advanced Solid Tumor 130Advanced Solid Tumors 122Solid Tumor 101Mesothelioma, Malignant 48Solid Tumors 43Mesothelioma 42Hematopoietic and Lymphatic System Neoplasm 30Solid Tumor, Adult 27Retinoblastoma 20Pancreatic Neoplasms 14Carcinoma, Non-Small-Cell Lung 14Ovarian Neoplasms 13Lung Neoplasms 13Neoplasms 11Advanced Malignant Solid Tumor 11Advanced or Metastatic Solid Tumors 10Solid Tumors, Adult 9Sarcoma 9Hematopoietic and Lymphoid System Neoplasm 9Advanced Malignant Solid Tumors 9Stomach Neoplasms 8Solid Tumor Malignancies 8Neoplasm Metastasis 8Melanoma 8Malignant Solid Tumors 8Malignant Solid Neoplasm 8Locally Advanced or Metastatic Solid Tumors 8Kidney Neoplasms 8Colorectal Neoplasms 8Advanced/Metastatic Solid Tumors 8

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Recruiting × Adenocarcinoma Of Esophagus × Other solid neoplasm × Clear all
NCT07277413 2026-04-03

A Study of IDE892 as Monotherapy and Combination in MTAP-deleted Advanced Solid Tumors

IDEAYA Biosciences

Phase 1 Recruiting
260 enrolled
GastrointestinalGenitourinaryOther solid neoplasmThoracic

Adenocarcinoma Of Esophagus, Esophageal Squamous Cell Carcinoma, Mesothelioma, Malignant, Urinary Bladder Neoplasms, Carcinoma, Transitional Cell, Mesothelioma, Neoplasm Metastasis, Recurrence

Data powered by HemOnc (CC BY 4.0) Colophon âš¡